<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;ff=20230828000943&amp;fc=2023070811404 7&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U- NVu8003KrCpq8yLQC -<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;ff=20230828000943&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 8 月 28 日星期一 04:09:44 +0000</lastbuilddate><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>冠状动脉血流能力和血运重建后的生存预测：生理学基础和临床意义</title><link/>https://pubmed.ncbi.nlm.nih.gov/37634192/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828000943&amp;v=2.17.9.post6+86293ac<description>结论：与 CFC 严重程度未进行血运重建相比，首次和重复血运重建后 CFC 严重减少，相关的观察到的生存概率有所改善。非严重 CFC 没有显示任何益处。血运重建后观察到的实际生存概率和虚拟假设生存概率之间的不一致表明存在残余 CAD 或失败血运重建。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 27 日：ehad579。doi：10.1093/eurheartj/ehad579。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：冠状动脉血流能力 (CFC) 与实际血运重建前后个体患者观察到的 10 年生存概率相关，以便与虚拟假设的理想完全血运重建进行比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用 Rb-82 正电子发射断层扫描 (PET) 绘制动脉特定尺寸的 CFC 图，对 6979 名冠状动脉疾病 (CAD) 受试者的应激性心肌灌注 (mL/min/g) 和每像素冠状动脉血流储备 (CFR) 进行量化-严重异常表示为左心室百分比 (%LV)，并进行前瞻性随访，将每十年的生存概率定义为 1.0 的分数。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：6979 名受试者的 CFC 严重减少，预测生存概率较低，与同等严重程度的未进行血运重建相比，血运重建后生存概率提高了 42% (P=0.0015)。对于 283 组术前和术后 PET 对，与区域 CFC 相关的区域性 CFC 严重减少血运重建后生存概率存在异质性改善（P&lt;0.001），搭桥手术后生存概率比经皮冠状动脉介入治疗后改善更大（P&lt;0.001），但正常化率仅为 5.7%；与严重 CFC 相比，非严重基线 CFC 或生存概率没有改善（P =0.00001).观察到的CFC=实际血运重建后的相关生存概率低于由于残余CAD或血运重建失败而导致的虚拟理想假设完全血运重建后生存概率(P&lt;0.001)，与性别或微血管功能障碍无关。2552年后CFC严重减少-与不重复手术相比，与低生存概率相关的血运重建受试者在重复血运重建后也得到改善（P=0.025）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与 CFC 严重程度未进行血运重建相比，首次和重复血运重建后 CFC 严重减少，相关的观察到的生存概率有所改善。非严重 CFC 没有显示任何益处。血运重建后观察到的实际生存概率和虚拟假设生存概率之间的不一致表明存在残余 CAD 或失败血运重建。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634192/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37634192</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad579>10.1093/eurheartj/ehad579</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634192</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator> K·兰斯·古尔德</dc:creator><dc:creator>尼尔斯·P·约翰逊</dc:creator><dc:creator>阿曼达·E·罗比</dc:creator><dc:creator>灵碧</dc:creator><dc:creator>达奈·基孔万</dc:creator><dc:creator>莫妮卡·B·帕特尔</dc:creator><dc:creator>阮东</dc:creator><dc:creator>理查德·柯基德</dc:creator><dc:creator>玛丽·海妮</dc:creator><dc:creator>萨尔曼·阿兰</dc:creator><dc:creator>康斯坦丁诺斯·查里塔基斯</dc:creator><dc:creator>阿比吉特·多布尔</dc:creator><dc:creator>——理查德·斯莫林</dc:creator><dc:creator>安吉洛·纳辛贝内</dc:creator><dc:creator>Marwan Jumean更多</dc:creator><dc:creator>萨钦·库马尔</dc:creator><dc:creator>比斯瓦吉特·卡尔</dc:creator><dc:creator>斯特凡诺·斯德林戈拉</dc:creator><dc:creator>安东尼·埃斯特雷拉</dc:creator><dc:creator>伊戈尔·格雷戈里姆</dc:creator><dc:creator>赖德建</dc:creator><dc:creator>李若莎</dc:creator><dc:creator>大卫·麦克弗森</dc:creator><dc:creator>贾加特·纳鲁拉</dc:creator><dc:date>2023-08-27</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>冠状动脉血流能力和血运重建后的生存预测：生理学基础和临床意义</dc:title><dc:identifier>下午：37634192</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad579</dc:identifier></item><item><title>心脏磁共振成像与计算机断层扫描指导经导管主动脉瓣置换术 (TAVR-CMR)：一项随机、开放标签、非劣效性试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37634187/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828000943&amp;v=2.17.9.post6+86293ac<description>背景：计算机断层扫描（CT）被推荐用于指导经导管主动脉瓣置换术（TAVR）。然而，由于相当大比例的 TAVR 候选者患有慢性肾脏病（CKD），碘造影剂的使用受到限制。CMR）是一种比较 CMR 与 CT 引导 TAVR 有效性的有希望的替代方案，但缺乏随机数据。方法：一项研究者发起的、前瞻性的、随机的、开放标签的、非劣效性试验…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 27 日。doi：10.1161/CIRCULATIONAHA.123.066498。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>计算机断层扫描（CT）被推荐用于指导经导管主动脉瓣置换术（TAVR）。然而，由于相当大比例的 TAVR 候选者患有慢性肾脏病（CKD），碘造影剂的使用受到限制。CMR）是一种<b>方法：</b>在两个奥地利心脏中心进行了一项研究者发起的前瞻性、随机、开放标签、非劣效性试验，对接受 TAVR 评估的患者进行了比较。根据纳入（严重症状性主动脉瓣狭窄）和排除标准（CMR、CT 或 TAVR 禁忌、预期寿命 &lt; 1 年、CKD 4 或 5）被随机（1:1）接受 CMR 或 CT 指导主要结局是根据瓣膜学术研究联盟 2 对出院时植入成功的定义进行定义，包括无手术死亡率、单个人工瓣膜的正确定位以及适当的人工瓣膜性能。使用混合方法评估非劣效性基于 9% 绝对风险差异裕度的改良意向治疗 (mITT)/按方案 (PP) 方法。<b>结果：</b> 2017 年 9 月 11 日至 2022 年 12 月 16 日期间，380 名 TAVR 候选者被随机分配至 CMR -引导（191例患者）或CT引导（189例患者）TAVR计划。其中，CMR引导组中的138例患者（72.3%）和CT引导组中的129例患者（68.3%）最终接受了TAVR（mITT）在这 267 名患者中，有 19 名患者出现方案偏差，从而形成 248 名患者的 PP 队列（n=121 例 CMR 引导，n=127 例 CT 引导）。CMR 组中有 129 名患者 (93.5%) 实现了这一目标，在 CT 组的 117 名患者 (90.7%) 中（组间差异为 2.8%；90% 置信区间 [CI]：-2.7 至 8.2%；p&lt;0.01 在 PP 队列 (n=248) 中，组间差异为 2.0%（90% CI：-3.8 至 7.8%；非劣效性 p&lt;0.01）。<b>结论：</b>就装置植入成功率而言，CMR 引导的 TAVR 并不劣于 CT 引导的 TAVR。因此，CMR 可以被视为 TAVR 规划的替代方案。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634187/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37634187</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066498>10.1161/CIRCULATIONAHA.123.066498</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634187</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator>马丁·雷德尔</dc:creator><dc:creator>伊万·莱希纳</dc:creator><dc:creator>玛格达莱娜·霍尔兹克内西特</dc:creator><dc:creator>克里斯蒂娜·蒂勒</dc:creator><dc:creator>普里西拉·芬克</dc:creator><dc:creator>弗里茨·奥伯霍伦泽</dc:creator><dc:creator>塞巴斯蒂安·冯·德·埃姆德</dc:creator><dc:creator>马蒂亚斯·帕明格</dc:creator><dc:creator>菲利克斯·特罗格</dc:creator><dc:creator>克里斯蒂安·克莱姆瑟</dc:creator><dc:creator>伊丽莎白·拉斯尼格</dc:creator><dc:creator>——凯瑟琳·丹宁格</dc:creator><dc:creator>罗纳德·宾德</dc:creator><dc:creator>汉诺·乌尔默</dc:creator><dc:creator>克里斯托夫·布伦纳</dc:creator><dc:creator>格特·克鲁格</dc:creator><dc:creator>阿克塞尔·鲍尔</dc:creator><dc:creator>伯恩哈德·梅茨勒</dc:creator><dc:creator>艾格尼丝·迈尔</dc:creator><dc:creator>塞巴斯蒂安·约翰内斯·赖因斯塔德勒</dc:creator><dc:date>2023-08-27</dc:date><dc:source>循环</dc:source><dc:title>心脏磁共振成像与计算机断层扫描指导经导管主动脉瓣置换术 (TAVR-CMR)：一项随机、开放标签、非劣效性试验</dc:title><dc:identifier>下午：37634187</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066498</dc:identifier></item><item><title>瞬时无波比率与血流储备分数相比：重新考虑当前建议的时间</title><link/>https://pubmed.ncbi.nlm.nih.gov/37634167/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828000943&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 27 日：ehad574。doi：10.1093/eurheartj/ehad574。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634167/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37634167</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad574>10.1093/eurheartj/ehad574</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634167</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator>米尔瓦特·阿拉斯纳格</dc:creator><dc:date>2023-08-27</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>瞬时无波比率与血流储备分数相比：重新考虑当前建议的时间</dc:title><dc:identifier>下午：37634167</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad574</dc:identifier></item><item><title>与血流储备分数相比，瞬时无波比指导的冠状动脉血运重建：DEFINE-FLAIR 和 iFR-SWEDEHEART 试验中 5 年死亡率的汇总</title><link/>https://pubmed.ncbi.nlm.nih.gov/37634165/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828000943&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 27 日：ehad552。doi：10.1093/eurheartj/ehad552。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634165/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37634165</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad552>10.1093/eurheartj/ehad552</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634165</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator>科林·贝瑞</dc:creator><dc:creator>约翰·D·麦克卢尔</dc:creator><dc:creator>基思·奥尔德罗伊德</dc:creator><dc:date>2023-08-27</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>与血流储备分数相比，瞬时无波比指导的冠状动脉血运重建：DEFINE-FLAIR 和 iFR-SWEDEHEART 试验中 5 年死亡率的汇总</dc:title><dc:identifier>下午：37634165</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad552</dc:identifier></item><item><title>慢性冠状动脉综合征中的新发房颤：CLARIFY 登记处</title><link/>https://pubmed.ncbi.nlm.nih.gov/37634147/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828000943&amp;v=2.17.9.post6+86293ac<description>结论：在 CCS 患者中，NOAF 很常见，并且与较差的预后密切相关。更强化的预防措施和更系统的 AF 筛查是否会改善该人群的预后值得进一步研究。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 27 日：ehad556。doi：10.1093/eurheartj/ehad556。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：关于慢性冠状动脉综合征（CCS）患者新发心房颤动（NOAF）的数据很少。本研究旨在描述 CCS 患者中 NOAF 的发生率、预测因素及其对心血管结局的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用来自国际（45 个国家）CLARIFY 登记处（稳定性冠状动脉疾病患者的前瞻性观察性纵向登记处）的数据。在 29,001 名基线时未曾报告过 AF 的 CCS 门诊患者中，诊断出至少有 1 次 AF/扑动发作的患者将 5 年随访期间的患者与整个研究期间窦性心律的患者进行比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：NOAF 的发生率为每 100 患者年 1.12 [95% 置信区间 (CI) 1.06-1.18]（5 年累积发生率：5.0%）。NOAF 的独立预测因素是年龄增加、体重指数增加、估计肾小球滤过率低、白人种族、酒精摄入量和左心室射血分数低，而高甘油三酯与较低的发病率相关。NOAF 与不良结果风险大幅增加相关，调整后的风险比为 2.01（95%） ). 心血管死亡、非致命性心肌梗塞或非致命性中风的复合物 CI 1.61-2.52)，心血管死亡 2.61 (95% CI 2.04-3.34)，非致命性死亡 1.64 (95% CI 1.07-2.50)致命性心肌梗死、全因死亡为 2.27 (95% CI 1.85-2.78)、因心力衰竭住院为 8.44 (95% CI 7.05-10.10)、大出血为 4.46 (95% CI 2.85-6.99)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在 CCS 患者中，NOAF 很常见，并且与较差的预后密切相关。更强化的预防措施和更系统的 AF 筛查是否会改善该人群的预后值得进一步研究。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634147/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37634147</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad556>10.1093/eurheartj/ehad556</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634147</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator>亚历山大·戈蒂埃</dc:creator><dc:creator>——法比安·皮卡德</dc:creator><dc:creator>——格雷戈里·杜克罗克</dc:creator><dc:creator>耶迪德·埃尔贝兹</dc:creator><dc:creator>金·M·福克斯</dc:creator><dc:creator>罗伯托·法拉利</dc:creator><dc:creator>——伊恩·福特</dc:creator><dc:creator>让-克洛德·塔迪夫</dc:creator><dc:creator>Michal Tendera更多</dc:creator><dc:creator>菲利普·加布里埃尔·施泰格</dc:creator><dc:date>2023-08-27</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>慢性冠状动脉综合征中的新发房颤：CLARIFY 登记处</dc:title><dc:identifier>下午：37634147</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad556</dc:identifier></item><item><title>与血流储备分数相比，当冠状动脉血运重建由无波比率指导时，五年主要瞬时心血管事件会增加：iFR-SWEDEHEART 和 DEFINE-FLAIR 试验的汇总分析。</title><link/> https://pubmed.ncbi.nlm.nih.gov/37634144/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828000943&amp;v=2.17.9.post6+86293ac<description>结论：与 FFR 相比，iFR 指导下的血运重建的五年全因死亡率和 MACE 发生率有所增加。两组的非计划血运重建和 MI 发生率相同。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 27 日：ehad582。doi：10.1093/eurheartj/ehad582。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：指南建议以缺血证据为指导对心外膜中间动脉狭窄进行血运重建。同样推荐血流储备分数 (FFR) 和瞬时无波比 (iFR)。两项主要随机试验的单独 5 年结果比较iFR 引导的血运重建的 FFR 表明 iFR 引导的血运重建后全因死亡率增加。本研究的目的是对 iFR-SWEDEHEART (NCT02166736) 和 DEFINE-FLAIR (NCT02166736) 的 5 年结果数据进行研究级荟萃分析。 NCT02053038）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：分析了主要不良心血管事件 (MACE) 及其各个组成部分 [全因死亡、心肌梗死 (MI) 和计划外血运重建] 的综合情况。原始 Kaplan-Meier 估计值、风险人数和事件数提取于使用 ipdfc 软件包（Stata 版本 18，StataCorp College Station，TX USA）进行 5 年跟踪和分析。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：总共分别有 2,254 名和 2,257 名患者进行了 iFR 和 FFR 指导的血运重建。iFR 组 [n = 1,128 (50.0 %)] 与 FFR 组 [n = 1021] 相比，血运重建更常被推迟。 (45.2%)；p=0.001]。在 iFR 指导组中，死亡、MACE、非计划血运重建和 MI 的人数分别为 188 例 (8.3%)、484 例 (21.5%)、235 例 (10.4%) 和 123 例。 5.5%) vs. FFR 组中的 143 (6.3%)、420 ​​(18.6%)、241 (10.7%) 和 123 (5.4%)。MACE 的风险比 [95% 置信区间 (CI)] 估计值为1.18 [1.035; 1.34]，全因死亡率 1.34 [1.08; 1.67]，计划外血运重建 0.99 [0.83; 1.19]，MI 1.02 [0.80; 1.32]。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与 FFR 相比，iFR 指导下的血运重建的五年全因死亡率和 MACE 发生率有所增加。两组的非计划血运重建和 MI 发生率相同。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634144/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37634144</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad582>10.1093/eurheartj/ehad582</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634144</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator>阿什坎·埃夫特卡里</dc:creator><dc:creator>埃米尔·尼尔森·霍尔克</dc:creator><dc:creator>杰尔默·韦斯特拉</dc:creator><dc:creator>尼尔斯·图·奥尔森</dc:creator><dc:creator>尼尔斯·亨利克·布鲁恩</dc:creator><dc:creator>莉塞特·奥克斯·詹森</dc:creator><dc:creator>托马斯·恩斯特罗姆</dc:creator><dc:creator>埃瓦尔德·霍伊·克里斯蒂安森</dc:creator><dc:date>2023-08-27</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>与血流储备分数相比，当冠状动脉血运重建由无波比率指导时，五年主要瞬时心血管事件会增加：iFR-SWEDEHEART 和 DEFINE-FLAIR 试验的汇总分析。</dc:title><dc:identifier>下午：37634144</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad582</dc:identifier></item><item><title>危及肢体的严重缺血和微血管转化：临床意义</title><link/>https://pubmed.ncbi.nlm.nih.gov/37634134/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828000943&amp;v=2.17.9.post6+86293ac<description>结论：这些发现描述了 CLTI 肌肉中微血管系统的渐进性、缺氧驱动的转变，这在病理上改变了血流动力学，并在低动脉驱动压下加剧了组织损伤。缺氧驱动的毛细血管扩张对于 CLTI 结果非常重要，因此应该进一步开发 CLTI 的诊断和治疗。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 27 日：ehad562。doi：10.1093/eurheartj/ehad562。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：严重肢体威胁性缺血（CLTI）的临床治疗重点是预防和治疗动脉粥样硬化性动脉闭塞。微血管病理学在疾病进展中的作用仍然很大程度上未明确，更重要的是尚未用于治疗。一项探索性研究是表征微血管系统在 CLTI 病理学中的作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用 CLTI 患者 (n=50) 的临床高分辨率成像和来自 CLTI 截肢的肌肉样本 (n=40) 分别在静息肌肉血流和微血管结构水平上描述 CLTI 的微血管病理学。慢性、低动脉驱动压力模拟兔缺血模型（n=24）与腺病毒血管内皮生长因子 A 基因转移一起用于研究微血管改变对肌肉结果的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：CLTI肌肉静息时微血管血流并未减少，但毛细血管通过时间缩短（P&lt;0.01）。CLTI肌肉微血管还表现出毛细血管扩张（P&lt;0.001），并随着肌纤维萎缩恶化和毛细血管与肌纤维分离而进一步动脉化。此外，在慢性缺血的兔子和健康、正常的兔子肌肉中，CLTI 样毛细血管转化会恶化小腿肌肉的力量产生（P&lt;0.05）和组织结果（P&lt;0.01）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这些发现描述了 CLTI 肌肉中微血管系统的渐进性、缺氧驱动的转变，这在病理上改变了血流动力学，并在低动脉驱动压下加剧了组织损伤。缺氧驱动的毛细血管扩张对于 CLTI 结果非常重要，因此应该进一步开发 CLTI 的诊断和治疗。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634134/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37634134</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad562>10.1093/eurheartj/ehad562</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634134</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator>桑特里·塔尔瓦宁</dc:creator><dc:creator>加林娜·沃斯</dc:creator><dc:creator>格蕾塔·尤索拉</dc:creator><dc:creator>奥利·豪特罗</dc:creator><dc:creator>卡里·卡利奥科斯基</dc:creator><dc:creator>塔尼娅·斯约罗斯</dc:creator><dc:creator>维科·尼库莱宁</dc:creator><dc:creator>朱尼·塔维赛宁</dc:creator><dc:creator>雅科·海托宁</dc:creator><dc:creator>克里斯特·弗里莫迪格</dc:creator><dc:creator>克里斯塔·哈波宁</dc:creator><dc:creator>托马斯·塞兰德</dc:creator><dc:creator>托米·莱蒂宁</dc:creator><dc:creator>哈里·H·哈科维尔塔</dc:creator><dc:creator>尤哈尼·克努蒂</dc:creator><dc:creator>尼海·拉哈姆·卡拉姆</dc:creator><dc:creator>尤哈·哈蒂凯宁</dc:creator><dc:creator>基莫·马基宁</dc:creator><dc:creator>塞波·伊拉·赫图阿拉</dc:creator><dc:creator>佩特拉·科皮萨洛</dc:creator><dc:date>2023-08-27</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>危及肢体的严重缺血和微血管转化：临床意义</dc:title><dc:identifier>下午：37634134</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad562</dc:identifier></item><item><title>体弱老年房颤患者从维生素 K 拮抗剂改用非维生素 K 拮抗剂口服抗凝剂的安全性：FRAIL-AF 随机对照试验的结果</title><link/>https://pubmed.ncbi.nlm.nih.gov/37634130/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828000943&amp;v=2.17.9.post6+86293ac<description>背景：使用维生素 K 拮抗剂 (VKA) 治疗的虚弱心房颤动 (AF) 患者是否应改用非维生素 K 口服抗凝剂 (NOAC) 尚不明确。方法：我们进行了一项务实、多中心、开放标签、随机对照优效性试验。患有虚弱的老年 AF 患者（年龄≥75 岁且格罗宁根虚弱指标 (GFI) 评分≥3）被随机分配从 INR 指导的 VKA 治疗转为 NOAC 或继续 VKA 治疗。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 27 日。doi：10.1161/CIRCULATIONAHA.123.066485。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>使用维生素 K 拮抗剂 (VKA) 治疗的虚弱心房颤动 (AF) 患者是否应改用非维生素 K 口服抗凝剂 (NOAC) 尚不明确。<b>方法：</b>我们进行了一项务实、多中心、开放标签、随机对照优效性试验。患有虚弱的老年 AF 患者（年龄≥75 岁且格罗宁根虚弱指标 (GFI) 评分≥3）被随机分配从 INR 指导的 VKA 治疗转为 NOAC 或继续 VKA 治疗。 &lt;30 mL/min/1.73 <sup>m2</sup>或瓣膜性 AF 被排除。随访期为 12 个月。针对主要结局（主要或临床相关的非主要出血）的发生计算原因特异性风险比 (HR)并发症，以先发生者为准，将死亡视为竞争风险。分析遵循意向治疗原则。次要结局包括血栓栓塞事件。<b>结果：</b> 2018 年 1 月至 2022 年 6 月期间，共有 2,621 名患者接受了资格筛查，1,330 名患者接受了资格筛查患者被随机化（平均年龄 83 岁，中位 GFI 4）。随机化后，由于存在排除标准，转为 NOAC 组的 6 名患者和继续使用 VKA 组的 1 名患者被排除，剩下 662 名患者从 VKA 转为向 NOAC 和 661 名意向治疗人群中继续 VKA 患者进行试验。在发生 163 起主要结局事件（切换组 101 例，继续组 62 例）后，根据预先设定的无效性分析，试验因无效而停止。我们的主要结局的 HR 为 1.69 (95% CI 1.23-2.32)。血栓栓塞事件的 HR 为 1.26 (95% CI 0.60 至 2.61)。<b>结论：</b>对于虚弱老年 AF 患者，将 INR 指导的 VKA 治疗转为 NOAC与持续 VKA 治疗相比，出血并发症更多，但血栓栓塞并发症却没有减少。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634130/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37634130</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066485>10.1161/CIRCULATIONAHA.123.066485</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634130</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator>琳达·P·乔斯顿</dc:creator><dc:creator>桑德·范·多恩</dc:creator><dc:creator>彼得·M·范德文</dc:creator><dc:creator>巴特·TG·科伦</dc:creator><dc:creator>梅尔基奥·尼尔曼</dc:creator><dc:creator>惠贝尔迪娜·L·科克</dc:creator><dc:creator>马丁·E·W·赫梅尔斯</dc:creator><dc:creator>门诺 V 豪氏威马</dc:creator><dc:creator>玛丽克·克鲁普</dc:creator><dc:creator>劳拉·M·费伯</dc:creator><dc:creator>宁克·M·维尔斯玛</dc:creator><dc:creator>Wim F 萌芽更多</dc:creator><dc:creator>——罗布·费恩希尔</dc:creator><dc:creator>亨克·J·阿德里安森</dc:creator><dc:creator>Kit C Roes更多</dc:creator><dc:creator>阿诺·W·锄头</dc:creator><dc:creator>弗兰斯·H·鲁滕</dc:creator><dc:creator>吉尔特·扬·吉尔辛</dc:creator><dc:date>2023-08-27</dc:date><dc:source>循环</dc:source><dc:title>体弱老年房颤患者从维生素 K 拮抗剂改用非维生素 K 拮抗剂口服抗凝剂的安全性：FRAIL-AF 随机对照试验的结果</dc:title><dc:identifier>下午：37634130</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066485</dc:identifier></item><item><title>双室性心律失常性心肌病：12 年自然史</title><link/>https://pubmed.ncbi.nlm.nih.gov/37634129/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828000943&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 27 日：ehad554。doi：10.1093/eurheartj/ehad554。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634129/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37634129</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad554>10.1093/eurheartj/ehad554</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634129</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator>玛丽亚·克里斯蒂娜·普罗科皮奥</dc:creator><dc:creator>弗朗西斯科·阿尔佩杜拉达</dc:creator><dc:creator>基娅拉·布恰雷利-杜奇</dc:creator><dc:date>2023-08-27</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>双室性心律失常性心肌病：12 年自然史</dc:title><dc:identifier>下午：37634129</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad554</dc:identifier></item><item><title>光学相干断层扫描引导或血管内超声引导经皮冠状动脉介入治疗：OCTIVUS 随机临床试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37634092/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828000943&amp;v=2.17.9.post6+86293ac<description>背景：与血管造影引导的 PCI 相比，血管内成像引导的经皮冠状动脉介入治疗 (PCI) 结合血管内超声 (IVUS) 或光学相干断层扫描 (OCT) 显示出更好的临床结果。临床结果尚不清楚。方法：在这项前瞻性、多中心、开放的研究中， -标签，实用性试验，我们随机分配 2008 名患有明显冠状动脉病变的患者接受 PCI... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 27 日。doi：10.1161/CIRCULATIONAHA.123.066429。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>与血管造影引导的 PCI 相比，血管内成像引导的经皮冠状动脉介入治疗 (PCI) 结合血管内超声 (IVUS) 或光学相干断层扫描 (OCT) 显示出更好的临床结果。临床结果尚不清楚。<b>方法：</b>在这项前瞻性、多中心、开放的研究中， -标签、实用性试验，我们以 1:1 的比例随机分配 2008 名接受 PCI 的患有显着冠状动脉病变的患者，接受 OCT 引导或 IVUS 引导的 PCI。主要终点是心脏原因死亡的复合终点、靶血管相关性心肌梗死或 1 年时缺血驱动的靶血管血运重建，这为 OCT 组与 IVUS 组相比的非劣效性提供了动力。还评估了安全性结果。<b>结果：</b> 1 年时，主要OCT 组 1005 名患者中有 25 名（Kaplan-Meier 估计，2.5%）发生终点事件，IVUS 组 1003 名患者中有 31 名（Kaplan-Meier 估计，3.1%）发生终点事件（绝对差异，-0.6 个百分点） ；单侧 97.5% 置信区间上限，0.97 个百分点；P&lt;0.001，非劣效性）。OCT 组为 1.4%]，IVUS 组为 15 名患者 [1.5%]，P=0.85）。 OCT 组主要手术并发症的发生率低于 IVUS 组（22 例 [2.2%] 比 37 例 [3.7%]，P=0.047），尽管没有观察到与影像学手术相关的并发症<b>。</b>就 1 年时心脏原因死亡、靶血管相关心肌梗死或缺血驱动的靶血管血运重建的综合发生率而言，OCT 引导的 PCI 并不劣于 IVUS 引导的 PCI。在解释试验时应考虑所选的研究人群和低于预期的事件发生率。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634092/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37634092</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066429>10.1161/CIRCULATIONAHA.123.066429</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634092</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator>姜道润</dc:creator><dc:creator>安正民</dc:creator><dc:creator>尹成哲</dc:creator><dc:creator>许承浩</dc:creator><dc:creator>赵润京</dc:creator><dc:creator>李哲贤</dc:creator><dc:creator>顺俊宏</dc:creator><dc:creator>林苏彬</dc:creator><dc:creator>金尚旭</dc:creator><dc:creator>元浩渊</dc:creator><dc:creator>吴俊赫</dc:creator><dc:creator>郑千崔</dc:creator><dc:creator>洪英俊</dc:creator><dc:creator>尹勇勋</dc:creator><dc:creator>金浩润</dc:creator><dc:creator>崔延佑</dc:creator><dc:creator>李振浩</dc:creator><dc:creator>尹永元</dc:creator><dc:creator>金秀重</dc:creator><dc:creator>张浩裴</dc:creator><dc:creator>朴德宇</dc:creator><dc:creator>朴胜正</dc:creator><dc:creator>奥克蒂弗斯调查员</dc:creator><dc:date>2023-08-27</dc:date><dc:source>循环</dc:source><dc:title>光学相干断层扫描引导或血管内超声引导经皮冠状动脉介入治疗：OCTIVUS 随机临床试验</dc:title><dc:identifier>下午：37634092</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066429</dc:identifier></item><item><title>血小板生成素-MPL受体复合物的结构是造血偏向的蓝图</title><link/>https://pubmed.ncbi.nlm.nih.gov/37633268/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828000943&amp;v=2.17.9.post6+86293ac<description>血小板生成素（THPO 或 TPO）是造血干细胞（HSC）维持和巨核细胞分化的重要细胞因子。在这里，我们报道了细胞外 TPO-TPO 受体（TpoR 或 MPL）信号复合物的 3.4 Å 分辨率冷冻电镜结构，揭示了同二聚体 MPL 激活的基础，并为遗传功能丧失性血小板减少症突变提供结构合理化。该结构指导 TPO 变体 (TPO^(mod)) 的工程设计，具有... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 22 日：S0092-8674(23)00852-8.doi: 10.1016/j.cell.2023.07.037.打印前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">血小板生成素（THPO 或 TPO）是造血干细胞（HSC）维持和巨核细胞分化的重要细胞因子。在这里，我们报道了细胞外 TPO-TPO 受体（TpoR 或 MPL）信号复合物的 3.4 Å 分辨率冷冻电镜结构，揭示了该结构指导了 TPO 变体 (TPO <sup>mod</sup> ) 的工程设计，具有从中性拮抗剂到部分激动剂和超级激动剂等一系列信号活动。部分激动剂 TPO <sup>mod</sup>将 JAK/STAT 与 ERK/AKT/CREB ​​激活解耦，驱动巨核细胞生成和血小板生成的偏差，而不会引起小鼠体内 HSC 的显着扩增，并在体外显示出对人类 HSC 的卓越维持。TPO 的主要作用，凸显了其潜在效用TPO <sup>mod</sup>在血液学研究和临床HSC移植中的应用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37633268/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37633268</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.07.037>10.1016/j.cell.2023.07.037</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37633268</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator>堤直隆</dc:creator><dc:creator>扎赫拉·马苏米</dc:creator><dc:creator>苏菲·C·詹姆斯</dc:creator><dc:creator>朱莉·塔克</dc:creator><dc:creator>豪克·温克尔曼</dc:creator><dc:creator>威廉·格雷</dc:creator><dc:creator>洛拉·K·皮克顿</dc:creator><dc:creator>露西·莫斯</dc:creator><dc:creator>史蒂文·C·威尔逊</dc:creator><dc:creator>纳撒内尔·卡夫尼</dc:creator><dc:creator>——凯文·M·裘德</dc:creator><dc:creator>科尼利厄斯·加蒂</dc:creator><dc:creator>雅各布·皮勒</dc:creator><dc:creator>伊恩·希区柯克</dc:creator><dc:creator>K克里斯托弗·加西亚</dc:creator><dc:date>2023-08-26</dc:date><dc:source>细胞</dc:source><dc:title>血小板生成素-MPL受体复合物的结构是造血偏向的蓝图</dc:title><dc:identifier>下午：37633268</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.037</dc:identifier></item><item><title> PINK1、Keap1 和 Rtnl1 调节发育过程中内质网的选择性清除</title><link/>https://pubmed.ncbi.nlm.nih.gov/37633267/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828000943&amp;v=2.17.9.post6+86293ac<description>通过自噬选择性清除细胞器，包括内质网 (ER) 和线粒体，在细胞健康中发挥着重要作用。在这里，我们描述了通过自噬进行的发育程序选择性 ER 清除。我们表明，帕金森病相关的 PINK1 以及 Atl 、Rtnl1 和 Trp1 受体，通过自噬调节 ER 清除。E3 泛素连接酶 Parkin 在 PINK1 下游发挥作用，是线粒体清除所必需的，同时在... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 21 日：S0092-8674(23)00862-0. doi: 10.1016/j.cell.2023.08.008. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">通过自噬选择性清除细胞器，包括内质网 (ER) 和线粒体，在细胞健康中发挥着重要作用。在这里，我们描述了通过自噬进行的发育程序选择性 ER 清除。我们表明，帕金森病相关的 PINK1 以及 Atl 、Rtnl1 和 Trp1 受体，通过自噬调节 ER 清除。E3 泛素连接酶 Parkin 在 PINK1 下游发挥作用，是线粒体清除所必需的，而在内质网清除中具有相反的功能。PINK1 通过影响 Rtnl1 和 Atl 来调节 ER 清除。PINK1 调节ER 吞噬受体 Rtnl1 的 Keap1 定位和 Keap1 依赖性泛素化的变化以促进 ER 清除。因此，PINK1 通过影响决定哪种细胞器的 Keap1 和 Parkin 依赖性底物泛素化的平衡来调节 ER 和线粒体的选择性清除通过自噬被去除。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37633267/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37633267</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.008>10.1016/j.cell.2023.08.008</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37633267</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator>王若曦</dc:creator><dc:creator>蒂娜·M·福蒂尔</dc:creator><dc:creator>飞柴</dc:creator><dc:creator>苗光彦</dc:creator><dc:creator>詹姆斯·L·沉</dc:creator><dc:creator>卢卡斯·雷斯特雷波</dc:creator><dc:creator>杰罗米·J·迪贾科莫</dc:creator><dc:creator>帕纳吉奥蒂斯·维伦萨斯</dc:creator><dc:creator>埃里克·巴赫里克</dc:creator><dc:date>2023-08-26</dc:date><dc:source>细胞</dc:source><dc:title>PINK1、Keap1 和 Rtnl1 调节发育过程中内质网的选择性清除</dc:title><dc:identifier>下午：37633267</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.008</dc:identifier></item><item><title> Circulating dipeptidyl peptidase 3 - New hope for a specific treatment to improve prognosis in cardiogenic shock?</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632844/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828000943&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 26:ehad568. doi: 10.1093/eurheartj/ehad568. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37632844/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37632844</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad568>10.1093/eurheartj/ehad568</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37632844</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Janine Pöss</dc:creator><dc:creator> Petra Büttner</dc:creator><dc:creator> Holger Thiele</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> European heart journal</dc:source><dc:title> Circulating dipeptidyl peptidase 3 - New hope for a specific treatment to improve prognosis in cardiogenic shock?</dc:title><dc:identifier> pmid:37632844</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad568</dc:identifier></item><item><title> Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632758/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828000943&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 26:ehad506. doi: 10.1093/eurheartj/ehad506. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37632758/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37632758</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad506>10.1093/eurheartj/ehad506</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37632758</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Colin Baigent</dc:creator><dc:creator> Rafael Sádaba</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> European heart journal</dc:source><dc:title> Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence</dc:title><dc:identifier> pmid:37632758</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad506</dc:identifier></item><item><title> 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632756/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828000943&amp;v=2.17.9.post6+86293ac<description> In October 2021, the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) jointly agreed to establish a Task Force (TF) to review recommendations of the 2018 ESC/EACTS Guidelines on myocardial revascularization as they apply to patients with left main (LM) disease with low-to-intermediate SYNTAX score (0-32). This followed the withdrawal of support by the EACTS in 2019 for the recommendations about the management of LM disease of the previous... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 26:ehad476. doi: 10.1093/eurheartj/ehad476. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> In October 2021, the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) jointly agreed to establish a Task Force (TF) to review recommendations of the 2018 ESC/EACTS Guidelines on myocardial revascularization as they apply to patients with left main (LM) disease with low-to-intermediate SYNTAX score (0-32). This followed the withdrawal of support by the EACTS in 2019 for the recommendations about the management of LM disease of the previous guideline. The TF was asked to review all new relevant data since the 2018 guidelines including updated aggregated data from the four randomized trials comparing percutaneous coronary intervention (PCI) with drug-eluting stents vs. coronary artery bypass grafting (CABG) in patients with LM disease. This document represents a summary of the work of the TF; suggested updated recommendations for the choice of revascularization modality in patients undergoing myocardial revascularization for LM disease are included. In stable patients with an indication for revascularization for LM disease, with coronary anatomy suitable for both procedures and a low predicted surgical mortality, the TF concludes that both treatment options are clinically reasonable based on patient preference, available expertise, and local operator volumes. The suggested recommendations for revascularization with CABG are Class I, Level of Evidence A. The recommendations for PCI are Class IIa, Level of Evidence A. The TF recognized several important gaps in knowledge related to revascularization in patients with LM disease and recognizes that aggregated data from the four randomized trials were still only large enough to exclude large differences in mortality.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37632756/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37632756</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad476>10.1093/eurheartj/ehad476</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37632756</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Robert A Byrne</dc:creator><dc:creator> Stephen Fremes</dc:creator><dc:creator> Davide Capodanno</dc:creator><dc:creator> Martin Czerny</dc:creator><dc:creator> Torsten Doenst</dc:creator><dc:creator> Jonathan R Emberson</dc:creator><dc:creator> Volkmar Falk</dc:creator><dc:creator> Mario Gaudino</dc:creator><dc:creator> John JV McMurray</dc:creator><dc:creator> Roxana Mehran</dc:creator><dc:creator> Milan Milojevic</dc:creator><dc:creator> Miguel Sousa Uva</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> European heart journal</dc:source><dc:title> 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG</dc:title><dc:identifier> pmid:37632756</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad476</dc:identifier></item><item><title> Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632743/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828000943&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: This study identifies cDPP3 as a novel marker of CS and increased mortality in patients with ACS. Circulating DPP3 offers prognostic information beyond established risk factors and improves early risk assessment. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 26:ehad545. doi: 10.1093/eurheartj/ehad545. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Dipeptidyl peptidase 3 (DPP3) is a protease involved in the degradation of angiotensin II which disturbs peripheral blood pressure regulation and compromises left ventricular function. This study examined the relationship of circulating DPP3 (cDPP3) with cardiogenic shock (CS) and mortality in patients presenting with acute coronary syndromes (ACS). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Plasma cDPP3 levels were assessed at baseline and 12-24 hours after presentation in patients with ACS prospectively enrolled into the multicentre SPUM-ACS study (n = 4787). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Circulating DPP3 levels were associated with in-hospital CS when accounting for established risk factors including the ORBI risk score (per log-2 increase, hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.05-1.82, P = 0.021). High cDPP3 was as an independent predictor of mortality at 30 days (HR 1.87, 95% CI 1.36-2.58, P &lt; 0.001) and at 1 year (HR 1.61, 95% CI 1.28-2.02, P &lt; 0.001) after adjustment for established risk factors and the GRACE 2.0 score. Compared to values within the normal range, persistently elevated cDPP3 levels at 12-24 hours were associated with 13.4-fold increased 30-day mortality risk (HR 13.42, 95% CI 4.86-37.09, P &lt; 0.001) and 5.8-fold increased 1-year mortality risk (HR 5.79, 95% CI 2.70-12.42, P &lt; 0.001). Results were consistent across various patient subgroups. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: This study identifies cDPP3 as a novel marker of CS and increased mortality in patients with ACS. Circulating DPP3 offers prognostic information beyond established risk factors and improves early risk assessment.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37632743/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37632743</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad545>10.1093/eurheartj/ehad545</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37632743</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Florian A Wenzl</dc:creator><dc:creator> Francesco Bruno</dc:creator><dc:creator> Simon Kraler</dc:creator><dc:creator> Roland Klingenberg</dc:creator><dc:creator> Alexander Akhmedov</dc:creator><dc:creator> Stefano Ministrini</dc:creator><dc:creator> Karine Santos</dc:creator><dc:creator> Konstantin Godly</dc:creator><dc:creator> Julia Godly</dc:creator><dc:creator> David Niederseer</dc:creator><dc:creator> Robert Manka</dc:creator><dc:creator> Andreas Bergmann</dc:creator><dc:creator> Giovanni G Camici</dc:creator><dc:creator> Arnold von Eckardstein</dc:creator><dc:creator> Barbara Stähli</dc:creator><dc:creator> Olivier Muller</dc:creator><dc:creator> Marco Roffi</dc:creator><dc:creator> Lorenz Räber</dc:creator><dc:creator> Thomas F Lüscher</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> European heart journal</dc:source><dc:title> Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes</dc:title><dc:identifier> pmid:37632743</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad545</dc:identifier></item><item><title> Heart Failure Medical Therapy Prior to Mitral Transcatheter Edge-to-Edge Repair: The STS/ACC Transcatheter Valve Therapy Registry</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632738/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828000943&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Under one-fifth of patients with LVEF &lt;50% who underwent MTEER for FMR in this US nationwide registry were prescribed comprehensive GDMT, with substantial variation across sites. Compared with no/single therapy, triple and double therapy prior to MTEER were independently associated with reduced risk of mortality or HFH one year after intervention. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 26:ehad584. doi: 10.1093/eurheartj/ehad584. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Guideline-directed medical therapy (GDMT) is recommended prior to mitral valve transcatheter edge-to-edge repair (MTEER) in patients with heart failure (HF) and severe functional mitral regurgitation (FMR). Whether MTEER is being performed on the background of optimal GDMT in clinical practice is unknown. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Patients with left ventricular ejection fraction (LVEF) &lt; 50% who underwent MTEER for FMR from July 23, 2019 to March 31, 2022 in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry were identified. Pre-procedure GDMT utilization was assessed. Cox proportional hazards models were constructed to evaluate associations between pre-MTEER therapy (no/single, double, or triple therapy) and risk of one-year mortality or HF hospitalization (HFH). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Among 4,199 patients across 449 sites, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, mineralocorticoid receptor antagonists, and angiotensin receptor-neprilysin inhibitor were used in 85.1%, 44.4%, 28.6%, and 19.9% prior to MTEER, respectively. Triple therapy was prescribed for 19.2%, double therapy for 38.2%, single therapy for 36.0%, and 6.5% were on no GDMT. Significant center-level variation in the proportion of patients on pre-intervention triple therapy was observed (0-61%; adjusted median odds ratio 1.48 [95% confidence interval (CI) 1.25-3.88]; P &lt; 0.001). In patients eligible for one-year follow-up (n = 2,014; 341 sites), the composite rate of one-year mortality or HFH was lowest in patients prescribed triple therapy (23.1%) compared with double (24.8%), single (35.7%), and no (41.1%) therapy (P &lt; 0.01 comparing across groups). Associations persisted after accounting for relevant clinical characteristics, with lower risk in patients prescribed triple therapy (adjusted hazard ratio [aHR] 0.73, 95% CI 0.55-0.97) and double therapy (aHR 0.69, 95% CI 0.56-0.86) prior to MTEER compared with no/single therapy. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Under one-fifth of patients with LVEF &lt;50% who underwent MTEER for FMR in this US nationwide registry were prescribed comprehensive GDMT, with substantial variation across sites. Compared with no/single therapy, triple and double therapy prior to MTEER were independently associated with reduced risk of mortality or HFH one year after intervention.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37632738/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37632738</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad584>10.1093/eurheartj/ehad584</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37632738</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Anubodh S Varshney</dc:creator><dc:creator> Miloni Shah</dc:creator><dc:creator> Sreekanth Vemulapalli</dc:creator><dc:creator> Andrzej Kosinski</dc:creator><dc:creator> Ankeet S Bhatt</dc:creator><dc:creator> Alexander T Sandhu</dc:creator><dc:creator> Sameer Hirji</dc:creator><dc:creator> Ersilia M DeFilippis</dc:creator><dc:creator> Pinak B Shah</dc:creator><dc:creator> Mona Fiuzat</dc:creator><dc:creator> Patrick T O&#39;Gara</dc:creator><dc:creator> Deepak L Bhatt</dc:creator><dc:creator> Tsuyoshi Kaneko</dc:creator><dc:creator> Michael M Givertz</dc:creator><dc:creator> Muthiah Vaduganathan</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> European heart journal</dc:source><dc:title> Heart Failure Medical Therapy Prior to Mitral Transcatheter Edge-to-Edge Repair: The STS/ACC Transcatheter Valve Therapy Registry</dc:title><dc:identifier> pmid:37632738</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad584</dc:identifier></item><item><title> Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of Three Tests</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632469/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828000943&amp;v=2.17.9.post6+86293ac<description> Background: Lipoprotein(a) is a risk factor for cardiovascular events and modifies the benefit of pcsk9 inhibitors (pcsk9i). Lipoprotein(a) concentration can be measured with immunoassays reporting mass or molar concentration or a reference measurement system employing mass spectrometry. Whether the relationships between lipoprotein(a) concentrations and cardiovascular events in a high-risk cohort differ across lipoprotein(a) methods is unknown. We compared the prognostic and predictive value of... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Aug 26. doi: 10.1161/CIRCULATIONAHA.123.066398. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> <b>Background:</b> Lipoprotein(a) is a risk factor for cardiovascular events and modifies the benefit of pcsk9 inhibitors (pcsk9i). Lipoprotein(a) concentration can be measured with immunoassays reporting mass or molar concentration or a reference measurement system employing mass spectrometry. Whether the relationships between lipoprotein(a) concentrations and cardiovascular events in a high-risk cohort differ across lipoprotein(a) methods is unknown. We compared the prognostic and predictive value of these types of lipoprotein(a) tests for major adverse cardiovascular events (mace). <b>Methods:</b> The odyssey outcomes trial compared the pcsk9i alirocumab with placebo in patients with recent acute coronary syndrome (acs). We compared risk of mace in the placebo group and mace risk reduction with alirocumab according to baseline lipoprotein(a) concentration measured by siemens n-latex nephelometric immunoassay (ia-mass, mg/dl), roche tina-quant® turbidimetric immunoassay (ia-molar, nmol/l), and a non-commercial mass spectrometry-based test (ms, nmol/l). Lipoprotein(a) values were transformed into percentiles for comparative modeling. Natural cubic splines estimated continuous relationships between baseline lipoprotein(a) and outcomes in each treatment group. Event rates were also determined across baseline lipoprotein(a) quartiles defined by each assay. <b>Results:</b> Among 11,970 trial participants with results from all 3 tests, baseline median (q1, q3) lipoprotein(a) concentrations were 21.8 (6.9, 60.0) mg/dl, 45.0 (13.2, 153.8) nmol/l, and 42.2 (14.3, 143.1) nmol/l for ia-mass, ia-molar, and ms, respectively. The strongest correlation was between ia-molar and ms (r=0.990), with nominally weaker correlations between ia-mass and ms (r=0.967) and ia-mass and ia-molar (r=0.972). Relationships of lipoprotein(a) with mace risk in the placebo group were nearly identical with each test with estimated cumulative incidences differing by ≤0.4% across lipoprotein(a) percentiles, and all were incrementally prognostic after accounting for ldl-c (all spline p≤0.0003). Predicted alirocumab treatment effects were also nearly identical for each of the three tests, with estimated treatment hazard ratios (hrs) differing by ≤0.07 between tests across percentiles and nominally less relative risk reduction by alirocumab at lower percentiles for all three tests. Absolute risk reduction with alirocumab increased with increasing lipoprotein(a) measured by each test, with significant linear trends across quartiles. <b>Conclusions:</b> In patients with recent acs, three lipoprotein(a) tests were similarly prognostic for mace in the placebo group and predictive of mace reductions with alirocumab at the cohort level.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37632469/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37632469</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066398>10.1161/CIRCULATIONAHA.123.066398</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37632469</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Michael Szarek</dc:creator><dc:creator> Esther Reijnders</dc:creator><dc:creator> J Wouter Jukema</dc:creator><dc:creator> Deepak L Bhatt</dc:creator><dc:creator> Vera A Bittner</dc:creator><dc:creator> Rafael Diaz</dc:creator><dc:creator> Sergio Fazio</dc:creator><dc:creator> Genevieve Garon</dc:creator><dc:creator> Shaun G Goodman</dc:creator><dc:creator> Robert A Harrington</dc:creator><dc:creator> L Renee Ruhaak</dc:creator><dc:creator> Markus Schwertfeger</dc:creator><dc:creator> Sotirios Tsimikas</dc:creator><dc:creator> Harvey D White</dc:creator><dc:creator> Ph Gabriel Steg</dc:creator><dc:creator> Christa Cobbaert</dc:creator><dc:creator> Gregory G Schwartz</dc:creator><dc:creator> ODYSSEY OUTCOMES Investigators</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> Circulation</dc:source><dc:title> Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of Three Tests</dc:title><dc:identifier> pmid:37632469</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.066398</dc:identifier></item><item><title> Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632455/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828000943&amp;v=2.17.9.post6+86293ac<description> Background: Hospitalization is recognized as a sentinel event in the disease trajectory of patients with heart failure (HF), but not all patients experiencing clinical decompensation are ultimately hospitalized. Outpatient intensification of diuretics is common in response to symptoms of worsening HF, yet its prognostic and clinical relevance, specifically in patient with HF with mildly reduced or preserved ejection fraction is uncertain. Methods: In this prespecified analysis of the DELIVER... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Aug 26. doi: 10.1161/CIRCULATIONAHA.123.066506. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> <b>Background:</b> Hospitalization is recognized as a sentinel event in the disease trajectory of patients with heart failure (HF), but not all patients experiencing clinical decompensation are ultimately hospitalized. Outpatient intensification of diuretics is common in response to symptoms of worsening HF, yet its prognostic and clinical relevance, specifically in patient with HF with mildly reduced or preserved ejection fraction is uncertain. <b>Methods:</b> In this <i>prespecified</i> analysis of the DELIVER trial, we assessed the association between various non-fatal worsening HF events (those requiring hospitalization, urgent outpatient visits requiring intravenous HF therapies, and outpatient oral diuretic intensification) and rates of subsequent mortality. We further examined the treatment effect of dapagliflozin on an expanded composite endpoint of CV death, HF hospitalization, urgent HF visit, or outpatient oral diuretic intensification. <b>Results:</b> In DELIVER, 4,532 (72%) patients experienced no worsening HF event, while 789 (13%) had outpatient oral diuretic intensification, 86 (1%) required an urgent HF visit, 585 (9%) had a HF hospitalization, and 271 (4%) died of CV causes as a first presentation. Patients with a first presentation manifesting as outpatient oral diuretic intensification experienced rates of subsequent mortality that were higher (10[8-12] per 100py) than those without a worsening HF event (4[3-4] per 100py) but similar to rates of subsequent death following urgent HF visit (10[6-18] per 100py). Patients with a HF hospitalization as a first presentation of worsening HF had the highest rates of subsequent death (35[31-40] per 100py). The addition of outpatient diuretic intensification to the adjudicated DELIVER primary endpoint (CV death, HF hospitalization, or urgent HF visit) increased the overall number of patients experiencing an event from 1,122 to 1,731 (a 54% increase). Dapagliflozin reduced the need for outpatient diuretic intensification alone (HR 0.72; 95% CI: 0.64-0.82) and when analyzed as a part of an expanded composite endpoint of worsening HF or CV death (HR 0.76; 95% CI: 0.69-0.84). <b>Conclusions:</b> In patients with HF with mildly reduced or preserved ejection fraction, worsening HF requiring oral diuretic intensification in ambulatory care was frequent, adversely prognostic, and significantly reduced by dapagliflozin.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37632455/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37632455</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066506>10.1161/CIRCULATIONAHA.123.066506</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37632455</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Safia Chatur</dc:creator><dc:creator> Muthiah Vaduganathan</dc:creator><dc:creator> Brian L Claggett</dc:creator><dc:creator> Jonathan W Cunningham</dc:creator><dc:creator> Kieran F Docherty</dc:creator><dc:creator> Akshay S Desai</dc:creator><dc:creator> Pardeep S Jhund</dc:creator><dc:creator> Rudolf A De Boer</dc:creator><dc:creator> Adrian F Hernandez</dc:creator><dc:creator> Silvio E Inzucchi</dc:creator><dc:creator> Mikhail N Kosiborod</dc:creator><dc:creator> Carolyn SP Lam</dc:creator><dc:creator> Felipe A Martinez</dc:creator><dc:creator> Sanjiv J Shah</dc:creator><dc:creator> Magnus Petersson</dc:creator><dc:creator> Anna-Maria Langkilde</dc:creator><dc:creator> John JV McMurray</dc:creator><dc:creator> Scott D Solomon</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> Circulation</dc:source><dc:title> Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial</dc:title><dc:identifier> pmid:37632455</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.066506</dc:identifier></item><item><title> Upgrade of right ventricular pacing to cardiac resynchronisation therapy in heart failure: a randomised trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632437/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828000943&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: In pacemaker or ICD patients with significant RVP burden and reduced ejection fraction, upgrade to CRT-D compared to ICD therapy reduced the combined risk of all-cause mortality, heart failure hospitalisation or absence of reverse remodelling. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 26:ehad591. doi: 10.1093/eurheartj/ehad591. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: De novo implanted cardiac resynchronisation therapy with defibrillator (CRT-D) reduces the risk of morbidity and mortality in patients with left bundle branch block, heart failure and reduced ejection fraction (HFrEF). However, among HFrEF patients with right ventricular pacing (RVP), the efficacy of CRT-D upgrade is uncertain. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: In this multicentre, randomised, controlled trial, 360 symptomatic (New York Heart Association class II-IVa) HFrEF patients with a pacemaker or implantable cardioverter defibrillator (ICD), high RVP burden ≥20%, and a wide, paced QRS complex duration ≥150 ms were randomly assigned to receive CRT-D upgrade (n = 215) or ICD (n = 145) in a 3:2 ratio. The primary outcome was the composite of all-cause mortality, heart failure hospitalisation or &lt;15% reduction of left ventricular end-systolic volume assessed at 12 months. Secondary outcomes included all-cause mortality or heart failure hospitalisation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Over a median follow-up of 12.4 months, the primary outcome occurred in 58/179 (32.4%) in the CRT-D arm vs. 101/128 (78.9%) in the ICD arm [odds ratio 0.11; 95% confidence interval (CI) 0.06-0.19; p &lt; 0.001]. All-cause mortality or heart failure hospitalization occurred in 22/215 (10%) in the CRT-D arm vs. 46/145 (32%) in the ICD arm (hazard ratio 0.27; 95% CI 0.16-0.47; p &lt; 0.001). The incidence of procedure- or device-related complications was similar between the two arms [CRT-D group 25/211 (12.3%) vs. ICD group 11/142 (7.8%)]. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: In pacemaker or ICD patients with significant RVP burden and reduced ejection fraction, upgrade to CRT-D compared to ICD therapy reduced the combined risk of all-cause mortality, heart failure hospitalisation or absence of reverse remodelling.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37632437/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37632437</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad591>10.1093/eurheartj/ehad591</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37632437</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Béla Merkely</dc:creator><dc:creator> Robert Hatala</dc:creator><dc:creator> Jerzy K Wranicz</dc:creator><dc:creator> Gábor Duray</dc:creator><dc:creator> Csaba Földesi</dc:creator><dc:creator> Zoltán Som</dc:creator><dc:creator> Marianna Németh</dc:creator><dc:creator> Kinga Goscinska-Bis</dc:creator><dc:creator> László Gellér</dc:creator><dc:creator> Endre Zima</dc:creator><dc:creator> István Osztheimer</dc:creator><dc:creator> Levente Molnár</dc:creator><dc:creator> Júlia Karády</dc:creator><dc:creator> Gerhard Hindricks</dc:creator><dc:creator> Ilan Goldenberg</dc:creator><dc:creator> Helmut Klein</dc:creator><dc:creator> Mátyás Szigeti</dc:creator><dc:creator> Scott D Solomon</dc:creator><dc:creator> Valentina Kutyifa</dc:creator><dc:creator> Attila Kovács</dc:creator><dc:creator> Annamária Kosztin</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> European heart journal</dc:source><dc:title> Upgrade of right ventricular pacing to cardiac resynchronisation therapy in heart failure: a randomised trial</dc:title><dc:identifier> pmid:37632437</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad591</dc:identifier></item><item><title> The BUDAPEST trial: a good grade for upgrades in heart failure with reduced ejection fraction</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632436/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828000943&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 26:ehad588. doi: 10.1093/eurheartj/ehad588. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37632436/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828000943&v=2.17.9.post6+86293ac">37632436</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad588>10.1093/eurheartj/ehad588</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37632436</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Cecilia Linde</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> European heart journal</dc:source><dc:title> The BUDAPEST trial: a good grade for upgrades in heart failure with reduced ejection fraction</dc:title><dc:identifier> pmid:37632436</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad588</dc:identifier></item></channel></rss>